China to Get Cut-Price Supplies of GlaxoSmithKline’s New HIV Drug

Glaxosmithkline's New HIV Drug

China to Get Cut-Price Supplies of GlaxoSmithKline’s New HIV Drug

China will get cut-price supplies of GlaxoSmithKline’s new HIV drug Tivicay, after an accord for a Shanghai-based – Desano Pharmaceuticals to turn into an additional manufacturer of the medicine’s active ingredient.

The joint effort between Desano Pharmaceuticals and GSK’s HIV unit ViiV Healthcare marks a change in the business atmosphere for the British drug-producer that was charged a record of a 3 billion Yuan (US$484 million) in September for fixing Chinese doctors.

At that moment, GSK promised to support access to its pharmaceutical locations in the country by growing local production of drugs, and adopting flexible pricing. On the other hand, a ViiV spokesperson said that the transactions with Desano originated before this commitment.

On Thursday, under the agreement declared by ViiV, Desano will manufacture the active pharmaceutical ingredient for dolutegravir, or Tivicay to add into the GSK/ViiV supply chain network for onward sale in China and other developing countries.

ViiV said that the move would permit it to offer a competitive supply of finished products, without determining the scale of price markdown. The spokesman said that the drug’s price in China would be in accordance with that charged in poor countries.

Anna Domanska
Anna Domanska is an Industry Leaders Magazine author possessing wide-range of knowledge for Business News. She is an avid reader and writer of Business and CEO Magazines and a rigorous follower of Business Leaders.

Recent Posts

UK watchdog whacks Amazon with probe for unfair data collection practices

UK watchdog whacks Amazon with probe for unfair data collection practices

The Competition and Markets Authority will focus on whether Amazon, Inc. favors merchants that use its delivery services.
1 day ago
Altice buys 12 percent stake in BT worth £2 billion

Altice buys 12 percent stake in BT worth £2 billion

Altice said it did not intend to make a bid for the British Telecoms company, though the takeover code also does not allow it to make an unsolicited buyout offer for six months wit
1 day ago
G7 countries agree on broad principles of minimum corporate tax deal

G7 countries agree on broad principles of minimum corporate tax deal

The world’s richest nations (G7) reached a landmark accord setting a global minimum corporate tax rate for multinationals. Would it be effective in tackling tax evasion and avoid
1 day ago
BC Partner goes the Continuation Fund way to strike a $7bn deal

BC Partner goes the Continuation Fund way to strike a $7bn deal

BC Partners, a UK private equity firm, has floated a “continuation fund” deal, one of Europe’s largest such deals, by transferring its 47 per cent stake in the academic publi
2 days ago
FDA approves Biogen’s $56,000 drug for Alzheimer’s

FDA approves Biogen’s $56,000 drug for Alzheimer’s

The Food and Drug Administration of the US approved on Monday Biogen Inc’s Aducanumab to treat Alzheimer’s disease amidst the controversy of its efficacy. Biogen has pr
3 days ago
UK watchdog’s plans for big banks to draw fair compete rules draws criticism

UK watchdog’s plans for big banks to draw fair compete rules draws criticism

Under UK Finance’s proposals, nine banks under investigation by the CMA would be obliged to fund a “future entity” for three years.
3 days ago